Context Therapeutics extends cash runway to Q1 2024, prioritizes key pipeline programs

Context Therapeutics Inc.

Cash runway extended to Q1 2024; deferring noncritical R&D and reducing overhead.
ONA-XR ELONA Phase 1b/2 trial with elacestrant for ER+/PR+/HER2- mBCa starts Q4 2022; data Q4 2023.
CLDN6xCD3 BsMAb candidate nomination Q4 2022; IND submission planned Q1 2024.
Preliminary data from ISTs: granulosa cell/endometrial cancer Nov 2022; breast cancer Dec 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.